H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma

American Journal of Translational Research

Volumn 7, Issue 10, 2015, Pages 1747-1764

  Li, Chao ^a   Lei, Bingxi ^a   Huang, Shuaibin ^a   Zheng, Meiguang ^a   Liu, Zhenghao ^a   Li, Zhongjun ^a   Deng, Yuefei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Glioma; H19; microRNA 675

Indexed keywords

CYCLIN DEPENDENT KINASE 6; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA H19; MICRORNA; MICRORNA 675; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING;

EID: 84947742070     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Wen PY and Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
2. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M and Phillips HS. A hierarchy of self-renewing tumorinitiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
3. Omuro A and DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-1850.
4. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
5. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, Min W, Bennett AM, Gregory RI, Ding Y and Huang Y. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 2013; 52: 101-112.
6. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G and Reik W. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 2012; 14: 659-665.
7. Okamura E, Matsuzaki H, Sakaguchi R, Takahashi T, Fukamizu A and Tanimoto K. The H19 imprinting control region mediates preimplantation imprinted methylation of nearby sequences in yeast artificial chromosome transgenic mice. Mol Cell Biol 2013; 33: 858-871.
8. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H and Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene 2015; 34: 3076-3084.
9. Shoshani O, Massalha H, Shani N, Kagan S, Ravid O, Madar S, Trakhtenbrot L, Leshkowitz D, Rechavi G and Zipori D. Polyploidization of murine mesenchymal cells is associated with suppression of the long noncoding RNA H19 and reduced tumorigenicity. Cancer Res 2012; 72: 6403-6413.
10. Venkatraman A, He XC, Thorvaldsen JL, Sugimura R, Perry JM, Tao F, Zhao M, Christenson MK, Sanchez R, Yu JY, Peng L, Haug JS, Paulson A, Li H, Zhong XB, Clemens TL, Bartolomei MS and Li L. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature 2013; 500: 345-349.
11. Medrzycki M, Zhang Y, Zhang W, Cao K, Pan C, Lailler N, McDonald JF, Bouhassira EE and Fan Y. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res 2014; 74: 6463-6473.
12. Chan LH, Wang W, Yeung W, Deng Y, Yuan P and Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene 2014; 33: 4857-4866.
13. Oh SH, Jung YH, Gupta MK, Uhm SJ and Lee HT. H19 gene is epigenetically stable in mouse multipotent germline stem cells. Mol Cells 2009; 27: 635-640.
14. Pidsley R, Dempster E, Troakes C, Al-Sarraj S and Mill J. Epigenetic and genetic variation at the IGF2/H19 imprinting control region on 11p15.5 is associated with cerebellum weight. Epigenetics 2012; 7: 155-163.
15. Kawahara M, Morita S, Takahashi N and Kono T. Defining contributions of paternally methylated imprinted genes at the Igf2-H19 and Dlk1-Gtl2 domains to mouse placentation by transcriptomic analysis. J Biol Chem 2009; 284: 17751-17765.
16. Guibert S, Zhao Z, Sjolinder M, Gondor A, Fernandez A, Pant V and Ohlsson R. CTCFbinding sites within the H19 ICR differentially regulate local chromatin structures and cisacting functions. Epigenetics 2012; 7: 361-369.
17. Matsuzaki H, Okamura E, Shimotsuma M, Fukamizu A and Tanimoto K. A randomly integrated transgenic H19 imprinting control region acquires methylation imprinting independently of its establishment in germ cells. Mol Cell Biol 2009; 29: 4595-4603.
18. Ding GL, Wang FF, Shu J, Tian S, Jiang Y, Zhang D, Wang N, Luo Q, Zhang Y, Jin F, Leung PC, Sheng JZ and Huang HF. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012; 61: 1133-1142.
19. Kim NH, Choi SH, Kim CH, Lee CH, Lee TR and Lee AY. Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target. J Invest Dermatol 2014; 134: 1075-1082.
20. Goodell MA. Parental permissions: H19 and keeping the stem cell progeny under control. Cell Stem Cell 2013; 13: 137-138.
21. Loke YJ, Galati JC, Morley R, Joo EJ, Novakovic B, Li X, Weinrich B, Carson N, Ollikainen M, Ng HK, Andronikos R, Aziz NK, Saffery R and Craig JM. Association of maternal and nutrient supply line factors with DNA methylation at the imprinted IGF2/H19 locus in multiple tissues of newborn twins. Epigenetics 2013; 8: 1069-1079.
22. Carrell DT. Aberrant methylation of the H19 imprinting control region may increase the risk of spontaneous abortion. Epigenomics 2013; 5: 23-24.
23. Xia B, Yang S, Liu T and Lou G. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer 2015; 14: 57.
24. Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P, Song Z, Qian C, Chen Y, Yang S and Wang Y. miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol 2013; 15: 578-588.
25. He D, Wang J, Zhang C, Shan B, Deng X, Li B, Zhou Y, Chen W, Hong J, Gao Y, Chen Z and Duan C. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer 2015; 14: 73.
26. Xie C, Lu H, Nomura A, Hanse EA, Forster CL, Parker JB, Linden MA, Karasch C and Hallstrom TC. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas. Mol Cancer 2015; 14: 93.
27. Zhang JF, He ML, Fu WM, Wang H, Chen LZ, Zhu X, Chen Y, Xie D, Lai P, Chen G, Lu G, Lin MC and Kung HF. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology 2011; 54: 2137-2148.
28. Huang D, Qiu S, Ge R, He L, Li M, Li Y and Peng Y. miR-340 suppresses glioblastoma multiforme. Oncotarget 2015; 6: 9257-9270.
29. Dudek KA, Lafont JE, Martinez-Sanchez A and Murphy CL. Type II collagen expression is regulated by tissue-specific miR-675 in human articular chondrocytes. J Biol Chem 2010; 285: 24381-24387.
30. Dey BK, Pfeifer K and Dutta A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev 2014; 28: 491-501.
31. Kim NH, Choi SH, Lee TR, Lee CH and Lee AY. Cadherin 11, a miR-675 target, induces N-cadherin expression and epithelial-mesenchymal transition in melasma. J Invest Dermatol 2014; 134: 2967-2976.
32. Douet-Guilbert N, Tous C, Le Flahec G, Bovo C, Le Bris MJ, Basinko A, Morel F and De Braekeleer M. Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies. Cancer Genet 2014; 207: 83-86.
33. Otto T and Sicinski P. The kinase-independent, second life of CDK6 in transcription. Cancer Cell 2013; 24: 141-143.
34. Paternot S, Colleoni B, Bisteau X and Roger PP. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell Cycle 2014; 13: 2879-2888.
35. Bellail AC, Olson JJ and Hao C. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun 2014; 5: 4234.
36. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Kramer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C and Frohling S. Requirement for CDK6 in MLLrearranged acute myeloid leukemia. Blood 2014; 124: 13-23.
37. Komori T. Regulation of Rb family proteins by Cdk6/Ccnd1 in growth plates. Cell Cycle 2013; 12: 2161-2162.
38. Singh NK, Kundumani-Sridharan V, Kumar S, Verma SK, Kotla S, Mukai H, Heckle MR and Rao GN. Protein kinase N1 is a novel substrate of NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular smooth muscle cell division and migration leading to inward blood vessel wall remodeling. J Biol Chem 2012; 287: 36291-36304.
39. van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R and Stam RW. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle 2014; 13: 834-844.
40. Shao Y, Qu Y, Dang S, Yao B and Ji M. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int 2013; 13: 51.
41. Baba Y, Watanabe M, Murata A, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, Sakamaki K, Nakao M and Baba H. LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin Cancer Res 2014; 20: 1114-1124.
42. Pekkonen P, Jarviluoma A, Zinovkina N, Cvrljevic A, Prakash S, Westermarck J, Evan GI, Cesarman E, Verschuren EW and Ojala PM. KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. Cell Cycle 2014; 13: 3670-3684.
43. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA and Maris JM. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013; 19: 6173-6182.
44. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN and Hung MC. Definition of PKC-alpha, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 2014; 74: 4822-4835.
45. Pauls E, Ruiz A, Badia R, Permanyer M, Gubern A, Riveira-Munoz E, Torres-Torronteras J, Alvarez M, Mothe B, Brander C, Crespo M, Menendez-Arias L, Clotet B, Keppler OT, Marti R, Posas F, Ballana E and Este JA. Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. J Immunol 2014; 193: 1988-1997.
46. Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schafer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zochbauer-Muller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M and Sexl V. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167-181.
47. Grossel MJ, Baker GL and Hinds PW. cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J Biol Chem 1999; 274: 29960-29967.
48. Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zochbauer-Muller S, Zuber J, Malumbres M, Kollmann K and Sexl V. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015; 125: 90-101.
49. Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, Brennan MF, Levine AJ and Harris CR. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res 2012; 18: 4612-4620.
50. Kollmann K and Sexl V. CDK6 and p16INK4A in lymphoid malignancies. Oncotarget 2013; 4: 1858-1859.